Read by QxMD icon Read

Metastatic endometrial cancer

Tom Van Nyen, Cristian P Moiola, Eva Colas, Daniela Annibali, Frédéric Amant
Endometrial cancer is the most common type of cancer of the female reproductive tract. Although prognosis is generally good for patients with low-grade and early-stage diseases, the outcomes for high-grade and metastatic/recurrent cases remain poor, since traditional chemotherapy regimens based on platinum and taxanes have limited effects. No targeted agents have been approved so far, although several new drugs have been tested without striking results in clinical trials. Over the last decades, many efforts have been made towards the establishment and development of preclinical models, aiming at recapitulating the structural and molecular determinants of the disease...
August 9, 2018: International Journal of Molecular Sciences
Tatjana Terzic, Anne M Mills, Sarah Zadeh, Kristen A Atkins, Krisztina Z Hanley
GATA binding protein 3 (GATA3) immunohistochemistry is primarily used as a marker of breast and urothelial differentiation, particularly in metastatic settings. In the gynecologic tract it also serves a robust marker for mesonephric and trophoblastic tumors. However, expression has also been described in more common malignancies of gynecologic tract including ovarian, endometrial, and cervical carcinomas. Data on the distribution of GATA3 expression in gynecologic malignancies is somewhat limited, particularly across different histologic subtypes of ovarian, endometrial, and cervical carcinomas...
July 27, 2018: International Journal of Gynecological Pathology
Andrea Papadia, Alessandro Buda, Maria Luisa Gasparri, Giampaolo Di Martino, Beatrice Bussi, Debora Verri, Michael D Mueller
INTRODUCTION: Aim of the study is to evaluate the impact of different doses of indocyanine green (ICG) on the sentinel lymph-node (SLN) mapping in endometrial cancer (EC). MATERIALS AND METHODS: A retrospective analysis of EC patients undergoing a laparoscopic SLN mapping at two institutions was performed. Two different injection protocols were used (protocol # 1: 5 mg/ml and a volume of 8 ml; protocol # 2: 1.25 mg/ml and a volume of 4 ml). In every case, the injection was intracervical...
July 24, 2018: Journal of Cancer Research and Clinical Oncology
Tabari M Baker, Sana Waheed, Viqar Syed
The matrix metalloproteinases (MMPs) are implicated in tumor invasion and metastasis. Given their multiple tumor promoting roles, MMPs are promising targets for the treatment of metastatic cancer. Using a siRNA library screen of 140 membrane trafficking genes, we identified 41 genes in HEC-1B and 36 in Ishikawa cancer cells that decreased metalloproteinases activity. The 16 genes common in both cancer cell lines that decreased MMPs activity are involved in cargo sorting, vesicle formation and vesicle recycling...
July 20, 2018: Experimental Cell Research
Rohit Gunan Ganju, Ossama Tawfik, Laura Brown, Allen M Chen, Andrea Jewell, Mindi TenNapel, Andrew Hoover
OBJECTIVE: Undifferentiated endometrial carcinoma (UEC) represents a recently recognized and rare diagnosis that is commonly misclassified on histopathologic evaluation. These cancers account for less than 10% of carefully reviewed series of endometrial cancers from academic medical centers. We reviewed a single-institutional experience with the management of UEC focusing on clinicopathologic characteristics and treatment outcomes. METHODS: The medical records of all patients treated for histologically proven endometrial carcinoma between 2007 through 2016 were reviewed...
July 20, 2018: International Journal of Gynecological Cancer
Tanja Ignatov, Holm Eggemann, Serban Dan Costa, Olaf Ortmann, Atanas Ignatov
PURPOSE: To evaluate the pattern of endometrial cancer recurrence according to its biological subtype in a large cohort of patients. PATIENTS AND METHODS: Patients were stage eligible if they had a description of registry risk of recurrence status and were not primary metastatic. Data were prospectively collected. The primary endpoints were the subtype-dependent pattern and time of recurrence. RESULTS: The median follow-up time was 84 months...
July 19, 2018: Journal of Cancer Research and Clinical Oncology
Megan Buechel, Anindya Dey, Shailendra Kumar Dhar Dwivedi, Aleia Crim, Kai Ding, Roy Zhang, Priyabrata Mukherjee, Kathleen N Moore, Liangxian Cao, Arthur Branstrom, Marla Weetall, John Baird, Resham Bhattacharya
With rising incidence rates, endometrial cancer is one of the most common gynecologic malignancies in the United States. While surgery provides significant survival benefit to early-stage patients, those with advanced or recurrent metastatic disease have a dismal prognosis. Limited treatment options include chemotherapy and radiation therapy. Hence there is a compelling need for developing molecularly targeted therapy. Here we show that the polycomb ring finger protein BMI1, also known as a stem cell factor, is significantly overexpressed in endometrial cancer cell lines, endometrial cancer patient tissues as well as in non-endometrioid histologies and associated with poor overall survival...
July 19, 2018: Molecular Cancer Therapeutics
Anna Myriam Perrone, Giulia Girolimetti, Martina Procaccini, Lorena Marchio, Alessandra Livi, Giulia Borghese, Anna Maria Porcelli, Pierandrea De Iaco, Giuseppe Gasparre
In the event of multiple synchronous gynecological lesions, a fundamental piece of information to determine patient management, prognosis, and therapeutic regimen choice is whether the simultaneous malignancies arise independently or as a result of metastatic dissemination. An example of synchronous primary tumors of the female genital tract most frequently described are ovarian and endometrial cancers. Surgical findings and histopathological examination aimed at resolving this conundrum may be aided by molecular analyses, although they are too often inconclusive...
July 13, 2018: International Journal of Molecular Sciences
Giacomo Corrado, Valentina Laquintana, Rossella Loria, Mariantonia Carosi, Laura de Salvo, Isabella Sperduti, Ashanti Zampa, Lucia Cicchillitti, Giulia Piaggio, Giuseppe Cutillo, Rita Falcioni, Enrico Vizza
BACKGROUND: Patients with endometrial cancer (EC) and presumably with good prognosis may develop a recurrence indicating that the classification of this tumor is still not definitive and that new markers are needed to identify a subgroup at risk of relapse. The cell adhesion molecule L1CAM is highly expressed in several human carcinomas and has recently been described as a new marker for endometrial and ovarian carcinomas. The aim of this study was to determine the relevance of L1CAM in recurrent EC...
July 6, 2018: Journal of Experimental & Clinical Cancer Research: CR
Elizabeth V Connor, Peter G Rose
Endometrial cancer is the most common gynecologic malignancy in the developed world, and its incidence is increasing. Mortality from this cancer has not improved in recent decades and is primarily driven by high-grade carcinomas that are more likely to present at an advanced stage and ultimately are more likely to recur. The prognosis for recurrent endometrial cancer is poor, especially for the 50% of these women that present with extrapelvic disease recurrence. As a standard of care, recurrent disease has been treated with platinum-based chemotherapy; however, new therapies are emerging as we identify drivers of proliferation and metastasis at the cellular and molecular levels...
July 4, 2018: Expert Review of Anticancer Therapy
Jalal Raoufi, Serhan Can İşcan, Candost Hanedan, Emine Elif Özkan, Sevim Süreyya Çerçi, Ebru Erdemoğlu, Evrim Erdemoğlu
Objective: There is scarce information about axillary lymph node involvement in gynecologic cancers. We analyzed the incidence of suspicious axillary lymph nodes in gynecologic cancers. Materials and Methods: We retrospectively analyzed the positron emission tomography/computed tomography findings of 251 patients with endometrial, cervical, and ovarian cancer. There is no cut-off value documented for axillary metastases from gynecologic cancers; therefore we adopted the cut-off standardized uptake values (SUVs) proclaimed in breast cancer...
June 2018: Turkish Journal of Obstetrics and Gynecology
Jia Xu, Douglas I Lin
Cyclin D1 (CCND1) is a core cell cycle regulator and is frequently overexpressed in human cancers, often via amplification, translocation or post-transcription regulation. Accumulating evidence suggests that mutations of the CCND1 gene that result in nuclear retention and constitutive activation of CDK4/6 kinases are oncogenic drivers in cancer. However, the spectrum of CCND1 mutations across human cancers has not been systematically investigated. Here, we retrospectively mined whole-exome sequencing data from 124 published studies representing up to 29,432 cases from diverse cancer types and sites of origin, including carcinoma, melanoma, sarcoma and lymphoma/leukemia, via online tools to determine the frequency and spectrum of CCND1 mutations in human cancers and their associated clinico-pathological characteristics...
2018: PloS One
Ozlen Saglam, Jose Conejo-Garcia
Programmed cell death-1 and programmed cell death ligand-1 (PD-1/PD-L1) blockage has become an important treatment modality after approval of pembrolizumab and nivolumab by Food and Drug Administration in advanced cancers. Patients with metastatic and recurrent cervical cancer have limited treatment options and usually receive palliative platinum-based chemotherapy without significant survival benefit. Recent studies provided support for usage of immune checkpoint inhibitors in advanced cervical cancer. Around 35% of cervical squamous cell carcinoma (C-SCC) and 17% of adenocarcinomas expressed PD-L1...
2018: Integrative Cancer Science and Therapeutics
Ena Arora, Muhammad Masab, Priyanka Mittar, Vishal Jindal, Sorab Gupta, Claudia Dourado
Currently, treatment options for patients with advanced or recurrent endometrial cancer remain limited. The current standard of care treatment for advanced endometrial carcinoma is a platinum doublet chemotherapy. Second-line treatment options overall are very limited. There is no optimal treatment option for patients who show disease progression with first-line therapy. Therefore, novel and more efficacious therapies for patients with advanced or recurrent disease are needed. Immune checkpoint inhibitors have demonstrated a very impressive safety profile and anti-tumor activity in patients with programmed death-ligand 1 (PD-L1) positive endometrial cancer who were pre-treated with chemotherapy...
April 23, 2018: Curēus
Syed S Mahmood, Carol L Chen, Natalie Shapnik, Udhay Krishnan, Harsimran S Singh, Vicky Makker
Background: Fulminant myocarditis has been reported in patients treated with immune checkpoint inhibitors. We present the first described case of acute immune-mediated myocarditis and myositis associated with durvalumab plus tremelimumab combination therapy. The patient was undergoing treatment for advanced endometrial cancer. Case presentation: A 75-year-old Caucasian female presented with difficulty ambulating due to neck protraction, imbalance, and increased shortness of breath with exertion 3 weeks after her first durvalumab and tremelimumab administration for advanced endometrial cancer...
August 2018: Gynecologic Oncology Reports
A Bashyam, A Stewart, K Potter, I Bagwan, V S Sunkaraneni
Endometrial carcinoma is the fourth most common cancer affecting women in the UK. Its most frequent sites of spread are to the pelvic and para-aortic lymph nodes, vagina and peritoneum. We report a case of a 63-year-old woman with known endometrial cancer who presented with left facial swelling and eye displacement. Investigations revealed an expansile soft-tissue density mass arising within the bone, centred on the left zygoma, with exophytic extension into the left maxillary antrum, infratemporal fossa and inferiorly into the orbit...
June 18, 2018: Annals of the Royal College of Surgeons of England
Mine Kiseli, Gamze Sinem Caglar, Asli Yarci Gursoy, Tolga Tasci, Tuba Candar, Egemen Akincioglu, Emre Goksan Pabuccu, Nurettin Boran, Gokhan Tulunay, Haldun Umudum
BACKGROUND: Gastrin-releasing peptide (GRP) is thought to play a role in the metastatic process of various malignancies. The more stable precursor of GRP, pro-GRP (ProGRP), has been shown to be secreted by neuroendocrine tumors. This study was designed to assess the validity of ProGRP as a diagnostic marker in endometrioid adenocarcinomas (EAs) of the endometrium. METHODS: Thirty-seven patients with a diagnosis of EA, 23 patients with endometrial hyperplasia, and 32 age-matched controls with normal endometrial histology were recruited for this study...
June 13, 2018: Gynecologic and Obstetric Investigation
Hui Wang, Tian-Tian Wang, Xiu-Ping Lv
AIM: We explored the role of miR-29b expression in endometrial cancer (EC) progression and patient prognosis. MATERIALS & METHODS: Patients with primary or metastatic EC (n = 356), patients with endometrial benign tumors (n = 149) and healthy female subjects (n = 155) were collected. We assessed the diagnostic value of miR-29b expression for EC using a receiver operating characteristic curve. RESULTS: The miR-29b expressions were lower in patients with primary or metastatic EC...
June 2018: Future Oncology
Peixin Dong, Ying Xiong, Junming Yue, Sharon J B Hanley, Hidemichi Watari
Although the oncogene MMSET (also known as NSD2 or WHSC1) has an essential role in malignancies, its impact on human endometrial cancer (EC) metastasis and the molecular mechanism of MMSET regulation are largely unknown. We report that MMSET was markedly upregulated in EC cell lines and EC tissues, and was significantly associated with poor survival in EC. MMSET overexpression greatly promoted EC cell invasion and sphere formation, whereas inhibition of MMSET reduced EC cell invasion and sphere formation. Importantly, Twist1 was required for MMSET-induced EC cell invasion and sphere formation...
May 1, 2018: Oncotarget
Peter Widschwendter, Emanuel Bauer, Nikolaus De Gregorio, Inga Bekes, Wolfgang Janni, Christoph Scholz, Thomas W P Friedl
OBJECTIVE: The requirement for and extent of lymphadenectomy in endometrial cancer is still controversial. Clinicopathological prognostic factors could be helpful to predict lymph node involvement and avoid therefore unnecessary lymphadenectomy. The aim of this study was to investigate which factors can predict lymph node involvement and how lymph node metastases are distributed in the pelvic and para-aortic regions. METHODS: This retrospective analysis was performed by analyzing data from patients with endometrial cancer treated with standard surgery and lymphadenectomy at the Department of Gynecology and Obstetrics of the University Hospital Ulm in 2000 to 2013...
July 2018: International Journal of Gynecological Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"